Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  • Marit Stockfelt
  • Anna-Carin Lundell
  • Merete Lund Hetland
  • Mikkel Østergaard
  • Till Uhlig
  • Marte Schrumpf Heiberg
  • Espen A Haavardsholm
  • Michael T Nurmohamed
  • Jon Lampa
  • Dan Nordström
  • Kim Hørslev Petersen
  • Bjorn Gudbjornsson
  • Gerdur Gröndal
  • Jonathan Aldridge
  • Kerstin Andersson
  • Kaj Blennow
  • Henrik Zetterberg
  • Ronald van Vollenhoven
  • Anna Rudin
Vis graf over relationer

BACKGROUND: The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid arthritis (RA). Protein levels of IFNα have not been measured in RA and it is unknown whether they associate with clinical characteristics or treatment effect.

METHODS: Patients with early untreated RA (n = 347) were randomized to methotrexate combined with prednisone, certolizumab-pegol, abatacept, or tocilizumab. Plasma IFNα protein levels were determined by single molecular array (Simoa) before and 24 weeks after treatment initiation and were related to demographic and clinical factors including clinical disease activity index, disease activity score in 28 joints, swollen and tender joint counts, and patient global assessment.

RESULTS: IFNα protein positivity was found in 26% of the patients, and of these, 92% were double-positive for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). IFNα protein levels were reduced 24 weeks after treatment initiation, and the absolute change was similar irrespective of treatment. IFNα protein positivity was associated neither with disease activity nor with achievement of CDAI remission 24 weeks after randomization.

CONCLUSION: IFNα protein positivity is present in a subgroup of patients with early RA and associates with double-positivity for autoantibodies but not with disease activity. Pre-treatment IFNα positivity did not predict remission in any of the treatment arms, suggesting that the IFNα system is distinct from the pathways of TNF, IL-6, and T-cell activation in early RA. A spin-off study of the NORD-STAR randomized clinical trial, NCT01491815 (ClinicalTrials), registered 12/08/2011, https://clinicaltrials.gov/ct2/show/NCT01491815 .

OriginalsprogEngelsk
Artikelnummer189
TidsskriftArthritis Research & Therapy
Vol/bind23
Udgave nummer1
Sider (fra-til)189
ISSN1478-6354
DOI
StatusUdgivet - 13 jul. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 70406151